Novartis terminates sale of Sandoz U.S. generic oral solids, dermatology portfolio to AurobindoSandoz will continue to operate its oral solids and dermatology business as part of the Sandoz U.S. business. Lupin launches generic MyforticMycophenolic acid delayed-release tablets had a market value of roughly $156 million, according to IQVIA data from February. Focus On: Upsher-Smith builds business with focus on novelty, quality As it moves into its second century in business, Upsher-Smith Labs is focusing on innovating and growing its product offerings while maintaining its high standards. Elite, Lannett launch generic Adderall XR Adderall XR, including generic versions, have a market value of approximately $1.3 billion for the 12 months ending January 2020, according to IQVIA. Zydus Cadila gets FDA OK for generic Lamictal Zydus Cadila's generic Lamictal will be available in six dosage strengths. NCPA survey: Pharmacists back access to experimental COVID-19 treatment Ninety percent of local pharmacists are reporting a shortage of hydroxychloroquine, according to an NCPA survey. Zydus gets FDA's tentative nod for generic Rytary Zydus Cadila's generic Rytary is indicated to treat Parkinson's disease. Cipla gets FDA green light for generic Nexium Nexium and its generic versions had a market of approximately $70 million for the 12 months ended November 2019, according to IQVIA. Amneal donates hydroxychloroquine sulfate to Texas Amneal is donating one million hydroxychloroquine sulfate tablets to Texas, following a donation of two million tablets to New York. Mylan voluntarily waives marketing exclusivity for generic Kaletra Mylan will enable generic applicants to be eligible for FDA approval if Kaletra is found effective in treating COVID-19. First Previous 161 162 163 164 165 Next Last
